---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-24-000054"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:25:53.666882+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibrx wins trade secrets trial against I-Mab; jury rejects all misappropriation claims

## Summary
- Jury found in favor of Inhibrx, rejecting I-Mab's allegations of misappropriation of trade secrets.
- Lawsuit filed March 1, 2022, claimed Inhibrx and CSO Brendan Eckelman improperly used I-Mab's proprietary info.
- Certain matters remain before the court; Inhibrx notes potential appeals or further proceedings.
- The verdict removes a significant legal overhang for Inhibrx.
- Inhibrx announced the jury verdict on November 4, 2024.

## SEC filing metadata
- accession: 0002007919-24-000054
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000054/0002007919-24-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791924000054/inhibrx-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-24-000054
- JSON: https://secwatch.observer/filing/0002007919-24-000054.json
- Plain text: https://secwatch.observer/filing/0002007919-24-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.